ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
LncRNAs signatures in gynecological cancers: ovarian and endometrial cancers.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long noncoding RNAs in female malignancies: critical review of molecular mechanisms, clinical gaps, and therapeutic perspectives.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian and endometrial cancers rank among the most common and deadliest cancers affecting women globally. One of the most important factors that impacts patient survival is how early the tumor is detected. Unfortunately, these cancers often present vague symptoms that usually don't show up until the disease is already in an advanced stage. This makes early diagnosis and screening quite difficult. As a result, researchers are actively seeking better diagnostic tools and treatment approaches. In recent years, non-coding RNAs (ncRNAs) have gained significant attention for their key roles in controlling various cellular activities, especially in cancer. Among them, long non-coding RNAs (lncRNAs) are being explored for their potential as therapeutic targets, as well as their usefulness as diagnostic markers and indicators of poor outcomes. This article focuses on how lncRNAs could be crucial in driving or suppressing cell growth, invasion, metastasis, cell death, and resistance to drugs in ovarian and endometrial cancers.
Indexed as
Identifiers
40790288What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.